<DOC>
	<DOC>NCT02007278</DOC>
	<brief_summary>The purpose of this study is to compare the effect of a fixed dose combination of vildagliptin plus metformin versus combination therapy of glimepiride plus metformin in glycemic variability in patients with type 2 diabetes who have not achieved adequate control of their disease prior to treatment with metformin monotherapy in optimal doses.</brief_summary>
	<brief_title>Glycemic Excursions in Type 2 Diabetic Patients With Vildagliptin and Metformin Versus Vildagliptin and Glimepiride</brief_title>
	<detailed_description />
	<mesh_term>Hypoglycemia</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>HbA1c between 8%10.5% in stable metformin dose (&gt;1500 mg/day), four weeks prior visit 1 Use of other antidiabetic oral therapy during the last 3 months (sulphonylurea, glitazones, GLP1 analogues, DPP4 inhibitors), except metformin Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>diabetes</keyword>
	<keyword>hypoglycemia</keyword>
	<keyword>glycemic variability</keyword>
	<keyword>vildagliptin</keyword>
	<keyword>glimepiride</keyword>
</DOC>